Press Releases

Dated: Friday 16 October 2009

Comment from Ian Carr, Joint Administrator of Alizyme plc and Alizyme Therapeutics Limited

" The Joint Administrators are pleased to announce the sale on 15 October 2009 of cetilistat, (the major product of Alizyme Therapeutics Limited) to Norgine BV. The initial consideration is £4.6m with provision for possible future revenues from a share of milestone and royalty payments.

The sale should enable a dividend to be paid to Alizyme plc, the largest creditor shown in Alizyme Therapeutics Limited's Statement of Affairs, which in turn should permit a small dividend to Alizyme plc shareholders.

It is not possible at this stage to be more precise as to dividend prospects for creditors and shareholders until realisations are completed and creditors claims adjudicated for both Alizyme plc and Alizyme Therapeutics Limited. The Joint Administrators will update creditors and shareholders as and when appropriate."

Grant Thornton UK LLP is a leading financial and business adviser with 30 locations nationwide. We are the UK member of Grant Thornton International, one of the world's leading international organisations of independently owned and managed accounting and consulting firms. Although Grant Thornton International is not a worldwide partnership, the firms share a commitment to providing the same high quality service to their clients wherever they do business.

Copyright © 2009 Grant Thornton UK LLP. All rights reserved.

Grant Thornton - advisers to the independently minded – www.grantthornton.co.uk

Back